ReviewFrontiers in medicine2025
Research progress and perspectives of non-coding RNAs in primary biliary cholangitis: from mechanisms to therapeutics.
Review in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Serum matrix metalloproteinase-7 as a diagnostic and prognostic biomarker in primary biliary cholangitis.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary biliary cholangitis (PBC), an autoimmune-mediated cholestatic liver disease with a female predominance, remains enigmatic in its pathogenesis despite advances in understanding immune dysregulation, bile acid dyshomeostasis, inflammatory cascades, gut-liver axis crosstalk, and sex-biased mechanisms. Although ursodeoxycholic acid is widely recognized as the first-line therapy, its variable efficacy underscores the need for novel biomarkers and targeted therapies. Non-coding RNAs (ncRNAs), though not encoding proteins, have emerged as promising candidates due to their pivotal regulatory roles in autoimmune processes. This review systematically delineates the interplay between ncRNAs (miRNAs, lncRNAs, circRNAs) and key PBC mechanisms, evaluates their diagnostic and therapeutic potential, and proposes future research frameworks to bridge molecular insights with clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.